Oric Pharmaceuticals
ORIC
Market cap $626M

8.87 USD

-0.25

2.74%

Updated Oct 22, 11:26 AM EDT

1 day

-2.74%

5 days

-7.80%

1 month

-17.33%

3 months

-17.03%

6 months

1.72%

Year to date

-2.95%

1 year

62.45%

5 years

-65.58%

About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Employees: 107

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

184% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 19

5.04% more ownership

Funds ownership: 95.2% [Q1] → 100.24% (+5.04%) [Q2]

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

1% more funds holding

Funds holding: 111 [Q1] → 112 (+1) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

46% less capital invested

Capital invested by funds: $882M [Q1] → $478M (-$404M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

69%

upside

Avg. target

$19.50

120%

upside

High target

$21

137%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target	137%upside $21	Buy Reiterated	18 Sept 2024
Wedbush David Nierengarten 49% 1-year accuracy 25 / 51 met price target	125%upside $20	Outperform Reiterated	10 Sept 2024
Stifel Bradley Canino 45% 1-year accuracy 15 / 33 met price target	125%upside $20	Buy Initiated	6 Sept 2024
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target	137%upside $21	Buy Reiterated	14 Aug 2024
Wedbush David Nierengarten 49% 1-year accuracy 25 / 51 met price target	125%upside $20	Outperform Reiterated	13 Aug 2024

See Analyst Rankings

Financial journalist opinion

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain.

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Initiated dosing of ORIC-944 in combinations with NUBEQA ® (darolutamide) and ERLEADA ® (apalutamide) in the ongoing Phase 1b trial for prostate cancer

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs.

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2024 (the “Grant Date”), ORIC® granted a total of 33,000 non-qualified stock options and 5,600 restricted stock units to two new non-executive employees who began their employment with ORIC® in July 2024.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients. Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively.

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Zacks Investment Research

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

See News Rankings

Charts implemented using Lightweight Charts™